Verzenio

Chemical Nameabemaciclib
Dosage FormTablet (oral; 50 mg, 100 mg, 150 mg, 200 mg)
Drug ClassKinase inhibitors
SystemFemale reproductive
CompanyEli Lilly and Company
Approval Year2017

Indication

  • Verzenio is indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
  • Verzenio is indicated in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
  • Verzenio is indicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
Last updated on 1/12/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Verzenio (abemaciclib) prescribing information.2020Eli Lilly and Company